The people
What they build
Open roles via the TechTO Job Board
Working at Novo Nordisk Canada
Browse open roles across the community on the TechTO Job Board — Canada’s most connected tech network. Novo Nordisk Canada’s roles show up here whenever they post.
Open roles on the TechTO Job Board ↗Or their own careers page: novonordisk.ca/careers ↗Jobs live on jobs.techto.org — the only structured source. We link to it rather than scraping career sites, so the board is always the source of truth.
On the TechTO stage
Every talk is searchable — ask the archive about Novo Nordisk Canada ↗
About
Novo Nordisk Canada is the Canadian affiliate of Novo Nordisk A/S, based in Mississauga, Ontario. The parent traces to 1923, when Nordisk Insulinlaboratorium was set up in Denmark to make insulin commercially; Novo and Nordisk competed until merging in 1989. In Canada the affiliate's obesity work began with Health Canada's February 2015 approval of Saxenda — liraglutide — as the first once-daily human GLP-1 analogue indicated for chronic weight management. Kate Hanna, then in communications there, spoke at TechTO's marketing event in September 2019 about a specific constraint on that work: Canadian pharmaceutical marketing rules had only weeks earlier begun to acknowledge social media in draft guidance, and she is not permitted by law to name a product and its indication in the same message.
Backers
A wholly owned Canadian affiliate of Novo Nordisk A/S, which is listed in Copenhagen and New York.
Quick answers
Where is Novo Nordisk Canada based?
Mississauga, Ontario. It is the Canadian affiliate of Novo Nordisk A/S, the Danish pharmaceutical company headquartered in Bagsværd.
What did its speaker talk about at TechTO?
Kate Hanna described marketing a Health Canada-approved obesity treatment under rules that had only weeks earlier started to acknowledge social media, and that forbid naming a product and its indication together.
When did Saxenda reach Canada?
Health Canada approved Saxenda in February 2015 as the first once-daily human GLP-1 analogue indicated for chronic weight management.